Induction of Nevi and Skin Tumors in Ink4a/Arf Xpa Knockout Mice by Neonatal, Intermittent, or Chronic UVB Exposures

Arne van Schanke,12 Gemma M.C.A.L. van Venrooj,2 Marjan J. Jongsmaj,2 H. Alexander Banus,4 Leon H.F. Mullenders,1 Henk J. van Kranen,5 and Frank R. de Gruijl2

Dermatology Department, University Medical Centre Utrecht, Utrecht, the Netherlands; Departments of Dermatology and Toxicogenetics, Leiden University Medical Centre, Leiden, the Netherlands; Laboratory of Vaccine-Preventable Diseases; and Toxicology, Pathology, and Genetics Department, National Institute of Public Health and the Environment, Bilthoven, the Netherlands

Abstract

Nevi and melanomas correlate to childhood and intermittent solar UV exposure, xeroderma pigmentosum patients run increased risk, and p16Ink4a expression is often lost in malignant progression. To ascertain the effect of these risk factors, pigmented hairless Ink4a/Arf−/−, Xpa−/− knockout mice were subjected to various combinations of neonatal [7,12-dimethylbenz[a]anthracene (DMBA) or UVB exposure] and adult treatments (12-O-tetradecanoylphorbol-13-acetate or subacute daily UVB exposure or intermittent overexposure). Nevii occurred earliest, grew largest, and were most numerous in mice exposed to DMBA followed by intermittent UVB overexposure [effect of six minimal edemal doses (MED), 1×2 weeks > 4 MED 1×/wk]. Neonatal UV exposure enhanced nevus induction but lost its effect after 200 days. The Xpa−/− mice proved exquisitely sensitive to UV-driven nevus induction, indicating the involvement of pyrimidine dimer DNA lesions, but Xpa+/− mice developed many more nevi (>40 per mouse) at high UV dosages not tolerated by Xpa−/− mice. Ink4a/Arf−/− mice developed most skin tumors faster, but surprisingly developed nevi slower than their heterozygous counterparts especially after neonatal UV exposure. Despite raising >1,600 nevi, only six melanomas arose in our experiments with Ink4a/Arf knockout mice (five of which in Xpa+/− mice at high UV dosages). In contrast to human nevi, these nevi lacked hotspot mutations in Braf or Ras genes, possibly explaining the lack of malignant progression in the Ink4a/Arf−/− mice. Hence, although our experiments did not effectively emulate human melanoma, they provided clear evidence that intermittent UV overexposure strongly stimulates and the Ink4a/Arf−/− genotype may actually impair nevus development. (Cancer Res 2006; 66(5): 2608-15)

Introduction

The most important environmental risk factor for skin cancers, including cutaneous malignant melanomas, is exposure to solar UV radiation. Epidemiologic studies indicate that unlike squamous cell carcinomas (SCC), cutaneous malignant melanomas are not associated with chronic exposure, but with sunburns, especially those in childhood (1). Another important risk factor for cutaneous malignant melanoma is inheritance of mutations in so-called melanoma genes, which predispose individuals to the development of melanoma. Thus far, familial clusters have led to the identification of two melanoma genes: CDKN2A and CDK4 (2). The CDKN2A gene encodes two proteins—p16Ink4a and p14Arf—p16Ink4a regulates cell cycle progression by inhibiting cyclin-dependent kinases, such as CDK4. Two exons in CDKN2A can form an alternative reading frame for the p14Arf protein (p19Ink4b in mice; ref. 3), which enhances p53 function by blocking MDM2 (4). Mutations in the CDKN2A tumor suppressor gene impair the function of p16Ink4a and/or p14Arf, thus facilitating “unauthorized” proliferation of cells with, for example, erroneous activation of the Ras pathway. This is illustrated by a highly increased N-Ras mutation frequency in melanomas of patients with germ line CDKN2A mutations (5). Uncontrolled proliferation may cause further mutation fixation in cells with (UV-) damaged DNA. Consequently, mice lacking both Ink4a and Arf have an enhanced sensitivity to tumorigenesis (6). Mice nulligous for either p16Ink4a or p19Arf crossed with Ras transgenes rapidly develop melanomas that lack expression of p19Arf or p16Ink4a, respectively, indicating that both products of the CDKN2A locus participate in melanoma suppression (7). Similarly, although CDKN2A is only completely lost or mutated in a minority of cutaneous malignant melanoma, most cutaneous malignant melanomas and their metastases lack p16Ink4a expression (8). The expression is usually high in nevi (9), which commonly bear activating mutations in the oncogenes Braf or N-Ras (9). Loss of p16Ink4a cell cycle control thus seems to give way to the mitogenic signaling from Ras or Braf and contributes to progression of nevi to cutaneous malignant melanoma (10).

Sunlight causes various types of DNA damage, such as pyrimidine dimers, of which the importance in skin tumorigenesis is exemplified by characteristic signature mutations found in oncogenes and tumor suppressor genes in nonmelanoma skin cancer (11, 12).

Pyrimidine dimers can be repaired accurately by nucleotide excision repair. People with the rare genetic disorder xeroderma pigmentosum lack nucleotide excision repair and are up to 1,000 times more prone to skin cancers, including melanoma, compared with the general population (13). This condition can result from mutations in components of the nucleotide excision repair system, such as Xpa.

In wild-type mice, treatment with only UV radiation does not induce melanomas, but UV can accelerate their formation in combined treatments with chemical carcinogens (14–16). Similarly, UV radiation can strongly enhance melanoma formation in transgenic mouse strains that spontaneously develop these tumors (17).

Mice with a targeted deletion of the Ink4a/Arf locus do not develop melanomas spontaneously nor when exposed to UV radiation or chemical carcinogens (6). However, crossbreeding these mice with H-RasG12V transgenic mice (carrying an activated

Note: A. van Schanke is currently at NV Organon, Toxicology and Drug Disposition Department, Schaijk, the Netherlands.

Requests for reprints: Frank de Gruijl, Dermatology Department, Leiden University Medical Centre, PO Box 9600, 2300RC Leiden, the Netherlands. Phone: 31-71-5262497; E-mail: f.de_gruijl@lumc.nl.

doi:10.1158/0008-5472.CAN-05-2476
Ras oncogene under a tyrosine promotor) raised the percentage of animals with melanomas from 2% in Ink4a/Arf wild types to 60% in Ink4a/Arf knockout, illustrating the importance of CDKN2A in preventing melanoma (18). H-Ras mutations in keratinocytes can be effectively induced in Xpa knockout mice by chronic UV irradiation, leading to the formation of papillomas; however, no melanomas were observed in these experiments (19). We hypothesized that if H-Ras (or N-Ras) mutations could also be induced in melanocytes by UVB irradiation of Xpa knockout mice, and in crosses with Ink4a/Arf knockout mice, these Ras mutations could lead to the development of melanomas. Moreover, loss of p16Ink633 was found to be related to malignant progression of (UV-induced) skin carcinomas (20). The specific UV regimen (chronic versus intermittent exposure) can be expected to be decisive for the efficacy of different types of skin cancers. Therefore, we ascertained the skin tumorigenic effect of various UV exposure regimens on pigmented hairless Ink4a/Arf knockout and Ink4a/Arf Xpa double-knockout mice, specifically looking at nevi induction (risk factor of melanomas and putative precursors) and progression to melanoma.

Materials and Methods

Mice. Ink4a/Arf knockout (courtesy of Drs. R. DePinho and L. Chin; ref 6) and Xpa knockout mice (courtesy of Dr. Van Steeg; ref 21) were crossbred (F2) in a pigmented hairless background (Hr, Charles River, Wilmington, MA). Cohorts of neonates from three to five nests of Ink4a/Arf−/−x Ink4a/ Arf−/− parents entered the experiments, thus reproducing these genotypes in approximately equal numbers; in experiment 1, all mice were Xpa−/−; in experiment 2, all mice were Xpa+/−.

Mice were kept as described (22) and permission was obtained from the Ethical Commission on Animal Experiments of the University Medical Center Utrecht, Utrecht, the Netherlands.

Chemical exposures. 7,12-Dimethylbenz(a)anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA) were purchased from Sigma (Zwijndrecht, the Netherlands). Mice of the relevant cohorts were topically treated once every fortnight; TPA twice a week (positive control); V, sham.

UVB exposure. For UVB exposure, cages were placed in an automatically time-switched irradiation setup (23) equipped with Philips TL12/40W lamps (Philips, Eindhoven, the Netherlands). The doses were expressed as multiples of the minimal edemal dose (MED, determined earlier; ref 24). For TL12/40W lamps, 1 MED equals 500 J/m2 UV in Xpa−/− mice and 62.5 J/m2 in Xpa+/− mice. Six MED was the highest tested dose that caused a clear sunburn without blistering or further complications that acutely compromised the condition of the animals (i.e., highest tolerated dose). For neonatal exposures, pups were exposed separately (to prevent shielding) to prevent compromising the condition of the animals (i.e., highest tolerated dose). For neonatal exposures, pups were exposed separately (to prevent shielding) to prevent compromising the condition of the animals (i.e., highest tolerated dose). For neonatal exposures, pups were exposed separately (to prevent shielding) to prevent compromising the condition of the animals (i.e., highest tolerated dose).

UVB exposure. For UVB exposure, cages were placed in an automatically time-switched irradiation setup (23) equipped with Philips TL12/40W lamps (Philips, Eindhoven, the Netherlands). The doses were expressed as multiples of the minimal edemal dose (MED, determined earlier; ref 24). For TL12/40W lamps, 1 MED equals 500 J/m2 UV in Xpa−/− mice and 62.5 J/m2 in Xpa+/− mice. Six MED was the highest tested dose that caused a clear sunburn without blistering or further complications that acutely compromised the condition of the animals (i.e., highest tolerated dose). For neonatal exposures, pups were exposed separately (to prevent shielding) to prevent compromising the condition of the animals (i.e., highest tolerated dose).

Experiment 1. This experiment aimed at optimizing a UVB irradiation scheme to induce melanocytic hyperplasia to form nevi based on a two-stage initiation/promotion protocol (16). First, five promotion treatments of adult mice were compared after neonatal application of DMBA. Subsequently, initiation with DMBA was compared with UV irradiation (4 MED at days 3, 4, and 5 of age) or sham treatment.

The regimens in the adulthood were as follows: I, daily exposure to a suberythemal dose of UVB (4/7 MED); II, an equal dose in a single weekly exposure (4 MED); III, exposure to the highest tolerated UVB dose (6 MED) once every fortnight; IV, TPA twice a week (positive control); V, sham. Neonatal treatments were compared using adult treatments I, III, and V. Two cohorts included Ink4a/Arf wild types (Table 1).

Experiment 2. Ink4a/Arf−/− mice (Xpa−/−) were neonatally exposed to DMBA, UV, or sham treated, followed by adult promotion treatment III. Doses were adapted (see above) to Xpa wild-type mice, which are less sensitive than Xpa−/− mice to the acute effects of UVB radiation and DMBA. To allow a complete comparison, we included a cohort of Ink4a/Arf knockout mice (Xpa−/−) receiving exactly the same low doses (expressed in J/m2 UV or μg DMBA) as the Ink4a/Arf knockout in an Xpa−/− background. The treatments for both experiments are summarized in Table 1.

Characterization of tumors. Mice were checked weekly to record tumors and other abnormalities (23), and kept until tumors >10 mm across developed, illness occurred, or until 16 months of age. After sacrifice, the organs were thoroughly screened for abnormalities and samples of nevi and (skin) tumors were collected in formalin. Paraffin-embedded 5 μm tissue sections were H&E stained and evaluated by experienced pathologists. To establish the diagnosis, immunohistochemical stainings were done with the following antibodies: polyclonal goat anti-mouse Trp-1 (1:100, Santa Cruz Biotechnology, Heidelberg, Germany), polyclonal goat anti-human Trp-2 (1:100, Santa Cruz Biotechnology), monoclonal mouse anti-human Melan-A/Mart-1 (1:500, clone A103, DAKO, Glostrup, Denmark), polyclonal rabbit anti-cow S100 (1:8,000, DAKO), monoclonal mouse anti-β-smooth muscle actin (1:10,000, clone 1A4, Sigma), and monoclonal mouse anticytokeratin (1:100, clone AE1/AE3, Chemicon, Temecula, CA).

Proliferative signaling in nevi was established by staining with polyclonal rabbit anti-human Ki-67 (1:1,000, Novocastra, Newcastle upon Tyne, United Kingdom), polyclonal rabbit anti-human pERK1/2 (1:200, Cell Signaling, Beverly, MA), and rabbit polyclonal anti-p53 (1:500, CM-5, Novocastra).

Sections from murine SCCs and colon cancers served as positive controls for proliferation markers.

Microdissection and mutation analyses. From mice of each treatment group, nevi over 2 mm in diameter (n = 46) and all melanomas (n = 6) were analyzed for mutations. Five-micrometer sections of nevi and melanomas were fixed on PEN foil-coated glass slides (Leica Microsystems, Wetzlar, Germany) and deparaffinized. Specimens (unstained) of at least 50 cells were microdissected using an AS LMD laser microdissection microscope (Leica Microsystems) and collected in 8 mL FLB buffer with Proteinase-K (NucleoSpin DNA Trace kit, Machery Nagel, Düren, Germany). DNA was isolated using NucleoSpin columns according to the instructions of the manufacturer.

Fragments of Braf exon 15, N-Ras exons 1 and 2, H-Ras exons 1 and 2, and K-Ras exons 1 and 2 were PCR amplified in single fashion (primers and fragment sizes; Table 2). PCR reactions contained 25 μL Hotstart Taq Master Mix (Qiagen, Venlo, the Netherlands), 60 pmol of each primer, and 5 μL DNA (~5 ng) per reaction (total volume 25 μL). PCR products were reamplified in a 25 μL reaction. Depending on sequencing direction (Table 2), the 5′ or 3′ end of the PCR product was biotinylated using biotinylated primers.

Biotinylated PCR products were immobilized on streptavidin Sepharose HB beads (B&L Systems, Maarssen, the Netherlands) in binding buffer [10 mmol/L Tris-HCl, 2 mol/L NaCl, 1 mmol/L EDTA, and 0.1% Tween 20 (pH 7.6)]. The beads were transferred to a 0.2 mol/L NaOH solution to separate the strands. The beads containing the biotinylated strand were washed in 10 mmol/L Tris-acetate (pH 7.6) and fed into a 96-well plate containing the pyrosequencing primer (0.15 μL, 100 pmol/μL) and annealing buffer [44.85 μL, 20 mmol/L Tris-acetate, and 2 mmol/L MgAc2 (pH 7.6)].

The plate was transferred into a PSQ96MA Pyrosequencing Machine (Pyrosequencing, Biotage, Uppsala, Sweden) where real-time sequencing was done of the sequences surrounding codon 599 of Braf; codons 12 and 13 of N-, H-, and K-Ras exon 1; and codon 61 of N-, H-, and K-Ras exon 2, respectively, with the PSQ96 SNP Reagent kit (B&L Systems). Pyrograms were analyzed for deviations from the wild-type sequence.

Along with each lot of PCR reactions, negative controls without DNA and controls without PSQ primer were run, as well as wild-type samples for each gene and exon. Positive controls involved DNA extracted from three papillomas in which H-Ras codon 12 mutations were established earlier by allele-specific oligohybridization (19). The same mutations (C>T in transcribed strand) showed up in our pyrosequencing assays.

Analyses and statistics. Kaplan-Meier plots were used for initial exploration of treatment and genotype effects. These effects were confirmed...
Table 1. Overview of tumor outcomes for all treatments in this study

A. Treatments, survival, and melanocytic tumors

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Adult treatment, d28-end</th>
<th>Ink4a</th>
<th>Survival (d)</th>
<th>Melanomas</th>
<th>Nevi</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>n−/n+/n+ t</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Experiment 1A*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1: 10 μg DMBA</td>
<td>None</td>
<td>12/12/0</td>
<td>226</td>
<td>0</td>
<td>59 108*</td>
</tr>
<tr>
<td>2: 10 μg DMBA</td>
<td>25 μg TPA 2×/wk</td>
<td>13/13/0</td>
<td>216</td>
<td>0</td>
<td>133 82**</td>
</tr>
<tr>
<td>3: 10 μg DMBA</td>
<td>35.7 J/m² UV/d</td>
<td>12/11/0</td>
<td>138</td>
<td>0</td>
<td>47 84**</td>
</tr>
<tr>
<td>4: 10 μg DMBA</td>
<td>250 J/m² UV/wk</td>
<td>7/8/0</td>
<td>120</td>
<td>0</td>
<td>62 66*</td>
</tr>
<tr>
<td>5: 10 μg DMBA</td>
<td>375 J/m² UV/2wk</td>
<td>11/6/0</td>
<td>139</td>
<td>0</td>
<td>132 52***</td>
</tr>
<tr>
<td>6: 10 μg DMBA</td>
<td>375 J/m² UV/2wk</td>
<td>0/8/16</td>
<td>160</td>
<td>1</td>
<td>142 62**</td>
</tr>
<tr>
<td>Experiment 1B †</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7: None</td>
<td>None</td>
<td>13/15/0</td>
<td>284</td>
<td>0</td>
<td>16 432***</td>
</tr>
<tr>
<td>8: 250 J/m² UV</td>
<td>None</td>
<td>8/7/0</td>
<td>256</td>
<td>0</td>
<td>13 300***</td>
</tr>
<tr>
<td>9: None</td>
<td>375 J/m² UV/2wk</td>
<td>13/6/0</td>
<td>190</td>
<td>0</td>
<td>48 146**</td>
</tr>
<tr>
<td>10: 250 J/m² UV</td>
<td>375 J/m² UV/2wk</td>
<td>10/8/0</td>
<td>171</td>
<td>0</td>
<td>48 88**</td>
</tr>
<tr>
<td>11: 250 J/m² UV</td>
<td>35.7 J/m² UV/d</td>
<td>7/11/6</td>
<td>143</td>
<td>0</td>
<td>23 152†</td>
</tr>
<tr>
<td>Experiment 2∥</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12: 100 μg DMBA</td>
<td>3,000 J/m² UV/2wk</td>
<td>7/12/0</td>
<td>140</td>
<td>1</td>
<td>808 51***</td>
</tr>
<tr>
<td>13: 2,000 J/m² UV</td>
<td>3,000 J/m² UV/2wk</td>
<td>14/13/0</td>
<td>235</td>
<td>1</td>
<td>53 205**</td>
</tr>
<tr>
<td>14: None</td>
<td>3,000 J/m² UV/2wk</td>
<td>9/11/0</td>
<td>254</td>
<td>3</td>
<td>53 195*</td>
</tr>
<tr>
<td>15: 10 μg DMBA</td>
<td>375 J/m² UV/2wk</td>
<td>4/6/7</td>
<td>229</td>
<td>0</td>
<td>18 133**</td>
</tr>
</tbody>
</table>

B. Outcomes of nonmelanocytic tumors

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Papillomas</th>
<th>Cysts</th>
<th>SCCs</th>
<th>Sarcomas</th>
<th>GL</th>
<th>OT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>t m</td>
<td>Yield</td>
<td>n</td>
<td>t m</td>
<td>Yield</td>
</tr>
<tr>
<td>1</td>
<td>74</td>
<td>133**</td>
<td>0.67**</td>
<td>19</td>
<td>175**</td>
<td>0.33**</td>
</tr>
<tr>
<td>2</td>
<td>212</td>
<td>82**</td>
<td>2.50**</td>
<td>10</td>
<td>—**</td>
<td>0.27**</td>
</tr>
<tr>
<td>3</td>
<td>287</td>
<td>98**</td>
<td>0.82**</td>
<td>9</td>
<td>172**</td>
<td>0.13**</td>
</tr>
<tr>
<td>4</td>
<td>64</td>
<td>66*</td>
<td>2.08*</td>
<td>2</td>
<td>—**</td>
<td>0*</td>
</tr>
<tr>
<td>5</td>
<td>109</td>
<td>80**</td>
<td>1.00**</td>
<td>6</td>
<td>238**</td>
<td>0.12**</td>
</tr>
<tr>
<td>6</td>
<td>245</td>
<td>90**</td>
<td>1.42**</td>
<td>2</td>
<td>—**</td>
<td>0.03**</td>
</tr>
<tr>
<td>7</td>
<td>5</td>
<td>—***</td>
<td>0.00**</td>
<td>17</td>
<td>408**</td>
<td>0.04**</td>
</tr>
<tr>
<td>8</td>
<td>14</td>
<td>287**</td>
<td>0.33**</td>
<td>40</td>
<td>115**</td>
<td>1.67*</td>
</tr>
<tr>
<td>9</td>
<td>94</td>
<td>111**</td>
<td>1.58**</td>
<td>24</td>
<td>133**</td>
<td>0.63**</td>
</tr>
<tr>
<td>10</td>
<td>93</td>
<td>102†</td>
<td>1.50†</td>
<td>9</td>
<td>—†</td>
<td>0.44†</td>
</tr>
<tr>
<td>11</td>
<td>183</td>
<td>96†</td>
<td>3.00†</td>
<td>42</td>
<td>103†</td>
<td>1.17†</td>
</tr>
<tr>
<td>12</td>
<td>707</td>
<td>51**</td>
<td>31.1**</td>
<td>26</td>
<td>167**</td>
<td>0.63**</td>
</tr>
<tr>
<td>13</td>
<td>27</td>
<td>275**</td>
<td>0**</td>
<td>114</td>
<td>83**</td>
<td>2.04**</td>
</tr>
<tr>
<td>14</td>
<td>102</td>
<td>231†</td>
<td>0.05†</td>
<td>25</td>
<td>175†</td>
<td>0†</td>
</tr>
<tr>
<td>15</td>
<td>55</td>
<td>119**</td>
<td>1.20**</td>
<td>5</td>
<td>—</td>
<td>0.20**</td>
</tr>
</tbody>
</table>

NOTE: Levels of significance for yields were obtained by ANOVA and for tumor-free survival by Cox regression (corrected for genotype effects). Abbreviations: GL, generalized lymphoma; OT, other tumors such as hemangiomas, papillomas of the conjunctiva, lung, brain, and colorectal tumors; ∑n, total number of tumors observed per group; ns, not significant.

*P < 0.05.
†DMBA treatment at day 3; UVB treatment at days 3, 4, and 5.
‡Numbers of Ink4a/Arf knockouts, heterozygotes, and wild types per group. All animals in experiment 1 were Xpa+/−; all animals in experiment 2 were Xpa+/+. 
§Yields were compared at 98 days (experiment 1A) or 140 days (experiments 1B and 2).
*For statistics, the group exposed weekly to 250 J/m² UV was used as reference group.
**P < 0.01.
††For statistics, the group exposed neonatally to 250 J/m² and in adulthood to 375 J/m² UV per fortnight was used as reference group.
¶For uniformity, statistical comparisons are based on homozygous knockouts and heterozygotes only.
∥For statistics, the group sham exposed neonatally and to 3,000 J/m² UV per fortnight in adulthood was used as reference group.
#Numbers refer to Table 1A.
*Could not be calculated (percentage of affected animals never reached 50).
***P < 0.001.
Exposure-Dependent Skin Tumors in Ink4a/Arf Xpa Mice

Table 2. PCR and pyrosequencing primers and mutations observed in nevi (n = 46) and melanomas (n = 6)

<table>
<thead>
<tr>
<th>Gene</th>
<th>PCR primers: universal biotinylated, gene-specific forward and reverse</th>
<th>Amplicon size</th>
<th>Pyrosequencing primer (sequencing direction)</th>
<th>Informative sequences (%)</th>
<th>Mutations found</th>
</tr>
</thead>
<tbody>
<tr>
<td>Braf exon 15</td>
<td>Uni-biotin-rev*, 5'-TTCTTCTTACTTA-CTGACCTCAGA-3'; 5'-AGGCTGTGGTCTCATAGATGCCATC-CAAAATAGCTCAGA-3'</td>
<td>127</td>
<td>GTGACTTTTGGTCTAGCCAC (forward)</td>
<td>60</td>
<td>None</td>
</tr>
<tr>
<td>N-Ras exon 1</td>
<td>Uni-biotin-rev, 5'-ACAGGTTTTTGGCTGCTGTA-3'; 5'-AGGCTGTGGTCTCATAGATTCA-TCCACAAAGTGGTCTCAG-3'</td>
<td>112</td>
<td>AACTGTTGTTGGTGGACC (reverse)</td>
<td>82</td>
<td>None</td>
</tr>
<tr>
<td>H-Ras exon 1</td>
<td>Uni-biotin-rev, 5'-CTGGCTAGAATGTGTCTTCT-3'; 5'-AGGCTGTGGTCTCATAGATTGAGCTGCTCAGGACTC-3'; 5'-CTTGGCTAGTCTGTCAGATGA-3'</td>
<td>122</td>
<td>AGGAGTACAGTGCCATGAG (forward)</td>
<td>70</td>
<td>C&gt;T, codon 60 (1 nevus)</td>
</tr>
<tr>
<td>K-Ras exon 1</td>
<td>Uni-biotin-rev, 5'-AGGGCTGCTGGATGAATGCTG-3'; 5'-AGGCTGCTGGATGCTGAGTTGCTGCTATTGCTG-3'; 5'-biotin-labeled-ATGACTGTTGCTCAGA-3'</td>
<td>118</td>
<td>AAACGACTTTGTTGGTGGAGC (forward)</td>
<td>89</td>
<td>G&gt;A, codon 13 (1 nevus)</td>
</tr>
<tr>
<td>K-Ras exon 2</td>
<td>Uni-biotin-rev, 5'-TGAGATATTCTGAGAACAGA-3'; 5'-AGGCTGCTGCTGTCAGATTGATTTTAAAACCCACCTAT-ATGTTGGA-3'</td>
<td>144</td>
<td>GATATTCTGACACACAGGAG (forward)</td>
<td>87</td>
<td>None</td>
</tr>
</tbody>
</table>

*5'-Biotin-GGACACCAGCTGATGTTA-3' (universal biotinylated forward primer).
15'-Biotin-GGGTCTGCTGTCCTAGATT-3' (universal biotinylated reverse primer).

Using the Cox proportional hazards model in SPSS 10 software package (SPSS, Chicago, IL). Effects of treatments on tumor yield were evaluated at the median survival of the shortest-lived group by ANOVA with post hoc tests by Bonferroni’s t test for multiple comparisons.

Results

Tumors. Depending on treatment, a variety of tumors and skin lesions developed as outlined in Table 1. When appropriate, genotype effects are given below in the text. Only six melanomas were observed, showing a low grade of differentiation and pigmentation with spindle-shaped cells, and a (diffuse) positivity for S100 or Melan-A/Mart-1. One melanoma occurred in an Ink4a/Arf+/+ Xpa+/+/ mouse (experiment 1) and five melanomas in Ink4a/Arf+/+ mice (experiment 2), with no obvious bias in genotype or treatment.

Nevi. Melanocytic nevi appeared as accumulations of melanocytes and pigment-loaded macrophages in the dermis. The vast majority of nevi showed no indications of malignancy, either on macroscopic or microscopic histologic inspection (7%, n = 114 evaluated).

Over the entire first experiment, nevi appeared significantly later in Ink4a/Arf+/+ Xpa+/− mice than in Ink4a/Arf+/− Xpa−/− mice (median latency, tav of 131 versus 82 days, respectively, P = 0.004; Fig. 1A); this difference was most pronounced with neonatal UV exposure followed by 6 MED every fortnight (tav: 140 days versus 74, P = 0.0022; Fig. 1B). Moreover, the overall numbers of nevi per animal (yields) were higher in Ink4a/Arf+/− compared with Ink4a/Arf−/−: 2.5 versus 0.8 nevi per animal at day 140. Notably, this was the only skin lesion in our study of which the induction was slowed down in the Ink4a/Arf null mice.

Neonatal treatment with DMBA, especially in combination with adult erythemal UVB overexposures, remarkably shortened tav and enhanced yields. Daily suberythemal exposure (4/7 MED) had no discernable effect on nevus development (Fig. 2A). Surprisingly, TPA had no significant effect on nevus-free survival, although it raised nevus yields >2-fold compared with controls that received only DMBA.

As 6 MED UVB per fortnight was the most effective stimulus of nevus development, this regimen was used to compare the effects of the neonatal treatments with DMBA, UVB, or no exposure. Although more slowly than DMBA, neonatal UVB also induced nevi as shown in Fig. 2B. Correspondingly, nevus yields dropped when DMBA was replaced by UVB.

Experiment 2 used Xpa wild-type mice that could be exposed to 10 times higher DMBA concentrations and 8 times higher UVB levels, as their acute sensitivity to these challenges was much lower than that of Xpa−/− mice.

Although the tav for nevi was almost identical for the groups exposed to DMBA and 6 MED UVB per fortnight, the yields eventually rose 5.5-fold higher in Xpa−/− than in Xpa+/− mice when both were exposed to their respective highest tolerated doses. When Xpa wild types were exposed to the same physical doses as...
the Xpa<sup>−/−</sup> mice, nevi appeared 2.5 times later than in Xpa<sup>+/−</sup> mice, and eventually reached 5.1-fold lower numbers (Fig. 2C).

**Papillomas.** Papillomas were morphologically presented as hyperplastic keratinocytes protruding from the epidermal surface and positive for pan-cytokeratin.

Over the entire first experiment, papillomas were slightly augmented in Ink4a/Arf<sup>−/−</sup> compared with Ink4a/Arf<sup>+/−</sup> mice ($t_{50}$ of 95 versus 108 days, respectively; $P = 0.03$; Fig. 1C). Correspondingly, the numbers of papillomas per animal were higher in Ink4a/Arf<sup>−/−</sup> Xpa<sup>−/−</sup> mice compared with Ink4a/Arf<sup>+/−</sup> Xpa<sup>−/−</sup> mice.

**Figure 1.** Effect of Ink4a/Arf genotype on carcinogen-induced tumorigenesis. A, nevus-free survival summed for all groups in experiment 1. B, nevus-free survival in Xpa<sup>−/−</sup> (Ink4a/Arf<sup>−/−</sup> and Ink4a/Arf<sup>+/−</sup>) mice neonatally exposed to 4 MED UV on days 3, 4, and 5, and subsequently to 4 MED/2 weeks. C, papilloma-free survival summed for all groups in experiment 1. D, SCC-free survival in mice neonatally exposed to DMBA and after 4 weeks to various UV regimes. The $P$ values represent log-rank test statistics. Note that all tumors except nevi were enhanced by Ink4a/Arf deficiency.

**Figure 2.** Effect of carcinogen treatments on tumor-free survival. A, optimization of the adult treatment regimen for nevi. B, comparison of neonatal treatments on nevogenic potential. The $P$ values in (A and B) represent log-rank test statistics. C, comparison of nevus yields between Ink4a/Arf Xpa and Ink4a/Arf mice exposed to the highest tolerated carcinogenic dose for Ink4a/Arf Xpa or Ink4a/Arf mice. D, same comparison for papillomas. C and D, points, mean; bars, SE.
All neonatal and adult treatments used in these studies raised papilloma yields and prevalences but the differences between adult treatment regimens were small and statistically insignificant. Generally, earlier onset of papillomas was associated with higher numbers of papillomas per animal (Table 1). The papilloma yields for Xpa wild-type mice (experiment 2) were remarkably higher than for Xpa−/− mice (experiment 1) when both were exposed at their respective highest tolerated doses. However, when the same physical doses were used, yields were slightly higher in Xpa−/− mice (Fig. 2D).

**Squamous cell carcinomas.** SCCs were characterized by infiltratively growing keratinocytes, keratinization, and a positive immunohistochemical staining with pan-cytokeratin.

On average, SCCs occurred ~3-fold earlier in Ink4a/Arf−/− Xpa−/− mice than in Ink4a/Arf+/− Xpa−/− mice, but this difference was not evident in the separate treatments due to the small numbers of tumors. The overall effect of genotype on UV-induced SCC formation is illustrated in Fig. 1D. SCCs appeared earlier and in higher numbers with 4/7 MED/d than with 4 MED weekly.

**Sarcomas.** S.c. pleiomorphic spindle cell tumors, morphologically presenting with a low grade of differentiation, often highly infiltrated with lymphocytes, densely vascularized, and negative for the immunohistochemical markers S100, Melan-A/Mart-1, Trp-1, and pan-cytokeratin were categorized as (unspecified) sarcomas.

Sarcoma prevalence was affected by Ink4a/Arf genotype and treatments. Although not evident from the small number of tumors in each treatment, averaged over the DMBA-treated groups in experiment 1, sarcoma yield was 3.5-fold higher in the Ink4a/Arf−/− mice compared with Ink4a/Arf+/− mice (P = 0.0055). Further, combinations of neonatal DMBA or UV exposure and adult intermittent erythemal UV exposure raised sarcoma yields (Table 1).

**Cysts.** Epidermal cysts in the dermis morphologically presented as spheres of inward differentiating keratinocytes converging on central keratin deposits and often contained melanin pigment.

The occurrence of cysts was not affected by the Ink4a/Arf genotype. Cysts appeared remarkably earlier and with higher yields in Xpa−/− mice exposed neonatally to UVB (UVB).

**Other tumors.** Generalized lymphoma appeared as large nodules of histologically proven lymphocytes in multiple organs, such as liver and spleen. Ink4a/Arf−/− mice were strongly predisposed to develop lymphomas as opposed to Ink4a/Arf+/− mice. None of the treatments had an effect on lymphoma-free survival.

Other tumors were rare and included s.c. hemangiomas, showing widely dilated and aberrantly growing vascular channels and internal tumors at various locations.

**Genetic analyses of nevi and melanomas.** PCR-amplified DNA extracted from microdissected nevi (n = 46) and melanomas (n = 6) gave informative sequences in 74% of the 287 samples tested. The vast majority of these samples contained no hotspot mutations in H-Ras, N-Ras, and K-Ras codons 12, 13, or 61 as found in UV and DMBA-induced tumors, or the Braf codon 599 mutation as found in human nevi. Two nevi, however, contained mutations in K-Ras exon 1 and N-Ras exon 2 (Table 2).

**Proliferation marker responses in nevi and melanomas.** Sections from 33 nevi were stained for phospho-ERK1/2, Ki-67, and p53 (melanin was bleached and murine skin carcinomas served as positive controls). All but one were found to be negative for pERK1/2, and all were negative for p53. The majority of nevi was negative for Ki-67. Only two nevi (6%) showed scattered Ki-67-positive cells; one contained a small nest of pERK1/2-positive cells that coincided with Ki-67 positivity. The two Ki-67 positive nevi originated from an Ink4a/Arf−/− Xpa−/− and an Ink4a/Arf−/− Xpa−/− mouse that both received neonatal sham treatment and biweekly 6 MED exposures. All six melanomas were negative for pERK1/2 but showed an abundance of Ki-67-positive cells.

**Discussion**

This study compared several neonatal and adult treatments for their effects on nevus and melanoma development in mice. Although nevi rarely progressed to melanomas, remarkable differences in nevus size, multiplicity, and nevus-free survival were observed between treatments. Intermittent exposures to erythemal UVB doses (4 MED/wk or 6 MED/fortnight) caused a marked increase in nevus size and number and corresponding decrease in nevus-free survival compared with groups receiving low daily exposure (4/7 MED) or controls receiving no treatment in adulthood. An accelerating effect of intermittent erythemal UVB exposures on nevi was also found when neonatal DMBA exposure was replaced by neonatal UVB exposures.

Together, these data confirm the epidemiologic observation in humans that sunburns increase nevus numbers in contrast to chronic low exposures (25). Furthermore, the contrasting effects of intermittent erythemal and daily suberythemal UVB exposures match well with earlier experiments: single erythemal exposures stimulated murine melanocyte proliferation, whereas fractionated exposures were ineffective (26). Similarly, exposure of human nevi to erythemogenic doses of UVB radiation led to an increase in proliferation markers within 4 days after exposure as opposed to repeated suberythmgogenic exposures (27). Taken together, these results show that erythemogenic UVB exposures are powerful stimuli of melanocyte proliferation and nevus formation, in contrast to equal total doses fractionated into suberythemal exposures. Given the release of melanocyte-stimulating cytokines and growth factors such as endothelin-1 and stem cell factor by keratinocytes in erythemis skin (28–30), it is conceivable that paracrine stimulation contributes to melanocyte proliferation induction and nevus development.

The chemical promoter TPA had only minor effects on nevus formation in our study and did not enhance melanoma formation in Tyr-Ras mice treated with DMBA (31). These results suggest that in doses that are effective on keratinocytic tumors, TPA is only a weak promotor of melanocyte hyperproliferation, in contrast to intermittent UVB overexposure.

Neonatal treatment with DMBA or UVB radiation enhanced, but was no prerequisite for, the formation of nevi (i.e., nevi also arose in untreated control mice and in mice UV exposed only in adulthood). The enhancement of nevus formation by neonatal UVB exposures resembles the epidemiologic finding that neonatal UVB exposures contribute to nevus development (32). The greater efficacy of DMBA than UV in neonatal exposure may result from several factors. First, DMBA dissolved in acetone may penetrate through the epidermis and dermis, whereas UV penetrates only the epidermis. Second, DMBA may increase DNA adducts in basal keratinocytes and stimulate DNA repair, whereas UV may only increase DNA adducts in basal keratinocytes. Third, melanin may provide better protection against UV radiation than against DMBA.

Besides the treatment effects, deficiencies in either Xpa or Ink4a/Arf showed prominent effects on nevus formation. When
mice were exposed to identical low doses, nevus numbers were 5-fold higher in Xpa+/− than in Xpa−/− mice, indicating a role of nucleotide excision repair in preventing nevus formation. However, the high acute sensitivity to UV radiation and DMBA prohibited higher exposures of Xpa−/− mice. When Xpa+/− mice were exposed to their highest tolerated dose, nevus numbers rose 27-fold higher than when these mice were exposed to an 8-fold lower dose, equal to the highest tolerated dose for Xpa−/− mice. Thus, the maximum attainable yield of nevi in Xpa+/− mice far exceeded that attainable in Xpa−/− mice (Fig. 3A versus B).

Remarkably, the combined p16Ink4a p19Arf deficiency inhibited nevus development, whereas most other skin tumors were stimulated by this deficiency. This may indicate that the critical cell cycle checkpoints upon UV irradiation are regulated differently in melanocytes than in keratinocytes. Our group found no apparent in vivo effects of Ink4a/Arf−/− genotype on UV-induced cell cycle arrest and apoptosis in keratinocytes, but a lack of p16 has been reported to abrogate UV-induced G2 arrest in melanoma cell lines (33). Such a failure in G2 arrest may conceivably compromise the survival of normal melanocytes with DNA damage and thus impair nevus development.

The regimens that most effectively induced nevi in our experiments (i.e., neonatal and intermittent UV exposure) were also related to increased melanoma risk in humans, but melanomas were rare in our experiments. In earlier experiments (16), DMBA treatment and subsequent exposure to UVB radiation produced melanomas in 25% of hairless mice; a substantially higher percentage than in our experiments. This discrepancy may possibly be attributed to differences in mouse strains and exposure regimens.

The experiments with Xpa+/− mice yielded more melanomas (in 8% of 64 carcinogenically challenged mice) than experiments with Xpa−/− mice (in 0.5% of 205 carcinogenically challenged mice). The lower carcinogenic dosages that had to be used on the Xpa−/− mice apparently very much restricted the melanoma yield attainable in these mice. No obvious preference for melanoma development in either Ink4a/Arf−/− or Ink4a/Arf+/− mice was noted, but the low number of melanomas hampers any firm conclusion beyond the fact that the present experiments were ineffective in raising melanoma. As opposed to the current UV-inducible melanoma models that are based on prior receptor tyrosine kinase pathway activation (34), we attempted to establish a UV-inducible melanoma model based on prior inactivation of the p16Ink4a and/or p14arf pathways. Although p16Ink4a−specific knock-in models form melanomas upon DMBA exposure (7, 35), their responses to UV exposure remain to be established.

Given the large increase of melanoma incidence in H-RasG12V mice when crossbred with Ink4a/Arf knockouts (18), it is questionable whether the present experiments with Ink4a/Arf knockout mice were effective in introducing oncogenic changes strong or specific enough to express the higher melanoma risk in these mice. To investigate this point more closely, we analyzed the experimentally induced nevi for hotspot mutations in Ras or Braf genes, activation of pERK1/2 (downstream of Ras), proliferative activity (i.e., cycling cells expressing Ki67), and p53 expression (halting cell cycle progression, e.g., in senescence).

We collected nevus biopsies from mice of various genotypes and different exposure regimens and microdissected pigmented sections to restrict samples to melanocytes. Pyrosequencing of the extracted and PCR-amplified DNA rarely detected activating Braf, N-, H-, and K-Ras hotspot mutations commonly found in human melanomas and nevi.

The absence of a strong expression of phosphorylated ERK1/2 indicated that this branch of the Ras pathway was not activated in the nevi. Moreover, Ki67 positive cells were generally rare in the nevi, indicating a very low proliferation. p53 expression was not found in nevi, indicating it played no role in stagnation of nevus growth.

Apparently, these nevi arose from a transient burst (or repeated bursts) of proliferation in some melanocytes which subsequently halted as a certain contiguous mass of melanocytes was formed. In contrast to the singular interfollicular melanocytes, the melanocytes in these nevi were deeply pigmented (impermeable to UV light), possibly indicating an advanced stage of differentiation. In contrast, Ki-67 stained positive in all melanomas, supporting the notion that these tumors were indeed malignant and highly proliferative.

Differences in the induction of nonmelanocytic tumors were most strongly determined by the differences in genotypes. The homozygous Xpa knockout led to an increased sensitivity for UV-induced SCCs and papillomas, as described earlier (19). Ink4a/Arf−/− mice had an increased susceptibility to spontaneous lymphoma formation and to UVB/DMBA–induced sarcomas, papillomas and SCCs. These results are consistent with earlier reports (6). The enhanced formation of papillomas and SCCs in the absence of a functional p16Ink4a gene supports the functional role of p16Ink4a mutations in human SCCs (20).

Treatment effects on nonmelanocytic tumors included the neonatal UVB-provoked augmentation of epidermal cysts, which differ morphologically to spontaneous cysts in hairless mice (36). This effect was only significant in experiment 2 with Xpa wild-type mice with higher dosages. Carcinomas tended to be more effectively induced by chronic than intermittent UV exposure, but this effect was not firm due to censoring deaths under the latter
regimen and consequently low numbers of carcinomas. This is in agreement with earlier observations that fractionation of exposure enhances SCC development (37). Remarkably, the incidence of papillomas was unaffected by dosage fractionation demonstrating that total accumulated exposure determines papilloma risk, regardless of the occurrence of sunburns.

In conclusion, intermittent erythematous UVB exposures were more effective in promoting nevus development than equal weekly dosages spread over daily suberythemal exposures, in contrast to the dose fraction effects on nonmelanocytic tumor types. Furthermore, the prevalence and growth of nevi were impaired in homozygous Ink4a/Arf knockouts compared with heterozygotes. Surprisingly, the multiple nevi induced in homozygous Ink4a/Arf knockout mice showed very little tendency to progress to malignant melanoma, which may be related to the lack of hotspot mutations in Braf and N-Ras genes.

Acknowledgments

Received 7/14/2005; revised 11/28/2005; accepted 12/22/2005.

Grant support: National Dutch Cancer Foundation grant RUI.2000.2301 and European Commission grant QLK4-1999-01084.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby identified as nonreviewed literature in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Heggert Rebelt (Dermatology, Leiden University Medical Centre) and Anja Westerman-de Vries (National Institute of Public Health and the Environment) for technical assistance. This article must therefore be hereby acknowledged for the kind gift of Xpa knockout mice; and Drs. R. DePinho and L. Chin (Dana-Farber Cancer Institute, Boston, MA) for providing p16Ink4a/p19Arf knockout mice.

References

Induction of Nevi and Skin Tumors in \textit{Ink4a/Arf Xpa} Knockout Mice by Neonatal, Intermittent, or Chronic UVB Exposures

Arne van Schanke, Gemma M.C.A.L. van Venrooij, Marjan J. Jongsma, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/66/5/2608

Cited articles
This article cites 36 articles, 6 of which you can access for free at:
http://cancerres.aacrjournals.org/content/66/5/2608.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/66/5/2608.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.